| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1079/BJN2002631 |
| P698 | PubMed publication ID | 12215182 |
| P2093 | author name string | Hunter JO | |
| Madden JA | |||
| P2860 | cites work | Microbial ecology of the gastrointestinal tract | Q22255628 |
| Management of the irritable bowel syndrome | Q31941893 | ||
| Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome | Q33422637 | ||
| Abnormal colonic fermentation in irritable bowel syndrome | Q33487908 | ||
| Gastrointestinal flora and its alterations in critical illness | Q33789276 | ||
| Food hypersensitivity and irritable bowel syndrome | Q33941195 | ||
| Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome | Q34512846 | ||
| Food intolerance and the irritable bowel syndrome | Q34532110 | ||
| Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients | Q34738753 | ||
| Fortnightly Review: Irritable bowel, irritable body, or irritable brain? | Q36901988 | ||
| Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study | Q37417328 | ||
| The control and consequences of bacterial fermentation in the human colon | Q37455596 | ||
| Lactobacilli and the normal human anaerobic microflora | Q40822029 | ||
| Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome | Q45229343 | ||
| Anxiety and irritable bowel syndrome. | Q51115626 | ||
| Relation between food provocation and systemic immune activation in patients with food intolerance. | Q55034198 | ||
| Probiotics | Q57241205 | ||
| Mechanism of action of dietary fibre in the human colon | Q59070207 | ||
| P921 | main subject | irritable bowel syndrome | Q838966 |
| probiotics | Q1816730 | ||
| P304 | page(s) | S67-72 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | British Journal of Nutrition | Q4970206 |
| P1476 | title | A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics | |
| P478 | volume | 88 Suppl 1 |
| Q37980065 | 1H NMR-based metabonomic applications to decipher gut microbial metabolic influence on mammalian health |
| Q43755644 | A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. |
| Q33433931 | A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. |
| Q33457416 | A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. |
| Q37994645 | A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics |
| Q37907937 | Abdominal bloating and distension: what is the role of the microbiota. |
| Q33416742 | Application of sequence-dependent electrophoresis fingerprinting in exploring biodiversity and population dynamics of human intestinal microbiota: what can be revealed? |
| Q26748468 | Biochemical Engineering Approaches for Increasing Viability and Functionality of Probiotic Bacteria |
| Q34366956 | Bloating and functional gastro-intestinal disorders: where are we and where are we going? |
| Q43250316 | Carbohydrate intolerance in patients with self-reported food hypersensitivity: comparison of lactulose and glucose |
| Q36620171 | Clinical metabolomics paves the way towards future healthcare strategies |
| Q37290683 | Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells. |
| Q35412870 | Compositional dynamics of the human intestinal microbiota with aging: implications for health. |
| Q58726014 | Dietary Nutrients, Proteomes, and Adhesion of Probiotic Lactobacilli to Mucin and Host Epithelial Cells |
| Q33811317 | Dietary intakes in people with irritable bowel syndrome. |
| Q37097581 | Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome |
| Q79320470 | Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial |
| Q36458417 | Emerging drugs for irritable bowel syndrome |
| Q37444882 | Experimental design for the formulation and optimization of novel cross-linked oilispheres developed for in vitro site-specific release of Mentha piperita oil. |
| Q53108833 | Fructo-oligosaccharides and fibre in enteral nutrition has a beneficial influence on microbiota and gastrointestinal quality of life. |
| Q52680609 | Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome. |
| Q51764655 | Gut Microbiota Alteration After Long-Term Consumption of Probiotics in the Elderly. |
| Q36508139 | Identification and validation of urinary metabolite biomarkers for major depressive disorder |
| Q41761911 | Intestinal fermentation in patients with self-reported food hypersensitivity: painful, but protective? |
| Q51276800 | Inulin oligofructose attenuates metabolic syndrome in high-carbohydrate, high-fat diet-fed rats. |
| Q36273383 | Live bacterial cells as orally delivered therapeutics |
| Q35914935 | Metabolomic applications to decipher gut microbial metabolic influence in health and disease |
| Q35691567 | Microbiota and the gut-brain axis |
| Q79890359 | Post-infectious irritable bowel syndrome |
| Q24681377 | Potential uses of probiotics in clinical practice |
| Q36111520 | Probiotic for irritable bowel syndrome in pediatric patients: a randomized controlled clinical trial |
| Q30478861 | Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation |
| Q36735647 | Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. |
| Q36237068 | Probiotics as a treatment strategy for gastrointestinal diseases? |
| Q37054666 | Probiotics in irritable bowel syndrome: an immunomodulatory strategy? |
| Q38035021 | Probiotics use to treat irritable bowel syndrome |
| Q39369440 | Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea |
| Q35118075 | Probiotics: Considerations for Human Health |
| Q37140861 | Providing dietary advice for the individual with a stoma |
| Q39269039 | Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study |
| Q26772962 | Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials |
| Q34557101 | Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential |
| Q35761007 | Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice |
| Q92561801 | Stigma and irritable bowel syndrome: a taboo subject? |
| Q33662740 | The ecological community of commensal, symbiotic, and pathogenic gastrointestinal microorganisms - an appraisal |
| Q36372849 | The effect of Lactobacillus brevis KB290 against irritable bowel syndrome: a placebo-controlled double-blind crossover trial |
| Q34665715 | The role of the intestinal microbiota in the development of atopic disorders. |
| Q37205403 | Update on irritable bowel syndrome and gender differences |
Search more.